Financial Performance - Revenue increased by RMB 53.3 million or 1.9% to RMB 2,904.1 million compared to the six months ended June 30, 2022[2] - Gross profit decreased by RMB 106.7 million or 5.2% to RMB 1,943.4 million, with a gross profit margin of 66.9%[2] - Net profit attributable to shareholders decreased by RMB 147.0 million or 49.5% to RMB 150.0 million[2] - EBITDA decreased by RMB 48.7 million or 5.3% to RMB 867.3 million[2] - Basic earnings per share were RMB 4.06, down from RMB 8.54 for the six months ended June 30, 2022[3] - Total revenue for the six months ended June 30, 2023, was RMB 2,904,108 thousand, an increase from RMB 2,850,826 thousand for the same period in 2022, representing a growth of approximately 1.9%[24] - The pre-tax profit for the six months ended June 30, 2023, was RMB 922,980 thousand, compared to RMB 800,742 thousand for the same period in 2022, indicating an increase of about 15.3%[25] - Total tax expense for the six months ended June 30, 2023, was RMB 83,634,000, an increase of 15.5% compared to RMB 72,187,000 for the same period in 2022[28] - The group’s total comprehensive income attributable to equity holders of the parent company for the six months ended June 30, 2023, was RMB (201) thousand, compared to RMB (140) thousand for the same period in 2022[18] Assets and Liabilities - Total assets as of June 30, 2023, were RMB 14,892.5 million, compared to RMB 14,762.4 million as of December 31, 2022[6] - Non-current assets increased to RMB 13,191.2 million from RMB 13,463.8 million[5] - Current assets totaled RMB 13,109.0 million, up from RMB 10,785.8 million[5] - Total equity attributable to equity holders of the parent increased to RMB 11,334.8 million from RMB 10,175.9 million[6] - Non-current liabilities decreased to RMB 2,698,179 thousand as of June 30, 2023, down from RMB 3,720,700 thousand as of December 31, 2022, representing a decline of about 27.4%[7] - Trade receivables and notes receivable as of June 30, 2023, amounted to RMB 1,876,917,000, an increase from RMB 1,435,170,000 as of December 31, 2022[31] - Trade payables as of June 30, 2023, totaled RMB 439,628,000, an increase from RMB 417,814,000 as of December 31, 2022[38] - The total amount of discounted notes receivable was RMB 1,783,389,000 as of June 30, 2023, compared to RMB 1,713,387,000 as of December 31, 2022[34] - As of June 30, 2023, the total interest-bearing bank and other borrowings amounted to RMB 8,372,648 thousand, an increase from RMB 7,642,713 thousand as of December 31, 2022[40][41] Corporate Governance and Compliance - The company has adopted new and revised International Financial Reporting Standards (IFRS) effective from January 1, 2023, which may impact the disclosures in the annual financial statements[12] - The board did not recommend the payment of an interim dividend for the six months ended June 30, 2023[2] - The company has adopted high standards of corporate governance, complying with all applicable codes except for a deviation regarding the separation of the roles of Chairman and CEO[107] - The independent auditor has reviewed the unaudited interim financial results for the six months ended June 30, 2023, in accordance with the relevant auditing standards[111] Research and Development - The R&D team consists of 908 employees, including 79 PhDs and 447 Master's degree holders, with 272 patents granted in China as of June 30, 2023[67] - The company has 39 products in various stages of development in China, including 18 oncology products and 15 central nervous system products[67] - The company continues to invest in four strategic therapeutic areas: oncology, central nervous system, cardiovascular, and metabolism[67] - The company has developed over 30 domestic and more than 10 international products in its pipeline, maintaining a high level in innovative drug delivery technologies[51] Market and Product Performance - The company recorded product sales revenue of RMB 2,784.5 million, representing an 18.7% growth, and total revenue of RMB 2,904.1 million during the reporting period[84] - In the oncology treatment sector, revenue decreased by 11.2% to RMB 910.3 million, while cardiovascular treatment revenue increased by 24.2% to RMB 977.9 million[54] - The company has established a strong competitive advantage in 12 major products across high-prevalence disease areas, with market share expected to grow or maintain current levels[54] - The product "Baituo Wei" is expected to have significant market potential in China, with rapid sales growth anticipated due to strategic collaboration with BeiGene[85] Strategic Initiatives - The company aims to enhance management efficiency and reduce unnecessary expenses to navigate macroeconomic challenges[89] - The sales team for core therapeutic areas will be expanded to solidify market position in oncology and deepen coverage in the central nervous system treatment field[89] - The company will actively seek partnerships and explore domestic and international markets to ensure sustainable growth[89] - The strategic partnership with Abacus Medicine Pharma Services grants exclusive distribution rights for NPP drugs in Hong Kong, initiated in January 2023[81]
绿叶制药(02186) - 2023 - 中期业绩